XNCR लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 107390 min ago

@ $19.46

जारी किया गया: 14 Feb 2024 @ 20:00

वापसी: 2.67%

पिछला सिग्नल: Feb 13 - 20:01

पिछला सिग्नल: खरीदें

वापसी: -3.52 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 01:30):

Stats
आज की मात्रा	355 716
औसत मात्रा	692 466
बाजार मूल्य	1.23B
EPS	$0 ( 2024-02-27 )
अगली कमाई की तारीख	( $-0.0900 ) 2024-05-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.61
ATR14	$0.0250 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-09	Cornelissen Bart Jan	Buy	190 194	Stock Option (Right to Buy)
2024-04-09	Cornelissen Bart Jan	Buy	42 265	Common Stock
2024-04-09	Cornelissen Bart Jan	Buy	0
2024-03-11	Kuch John J	Sell	849	Common Stock
2024-03-11	Eckert Celia	Sell	850	Common Stock

INSIDER POWER
65.94
Last 96 transactions
Buy: 2 831 480 \| Sell: 458 022

मात्रा सहसंबंध

लंबा: -0.17 (neutral)

छोटा: -0.79 (moderate negative)

Signal:(19.267) Neutral

Xencor Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
THRX	0.898
WDC	0.891
PALT	0.886
TREE	0.883
OZKAP	0.882
OTRK	0.881
XPEL	0.873
HLMN	0.871
MBIO	0.869
TCBIO	0.862

10 सबसे अधिक नकारात्मक सहसंबंध
GLDI	-0.814
CFV	-0.804

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Xencor Inc सहसंबंध - मुद्रा/वस्त्र

-0.40
( neutral )

-0.10
( neutral )

0.00
( neutral )

-0.47
( neutral )

0.45
( neutral )

-0.10
( neutral )

Xencor Inc वित्तीय

Annual	2023
राजस्व:	$168.34M
सकल लाभ:	$156.84M (93.17 %)
EPS:	$-2.08

FY	2023
राजस्व:	$168.34M
सकल लाभ:	$156.84M (93.17 %)
EPS:	$-2.08

FY	2022
राजस्व:	$164.58M
सकल लाभ:	$155.78M (94.65 %)
EPS:	$-0.930

FY	2021
राजस्व:	$275.11M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$1.440

Financial Reports:

No articles found.

Xencor Inc

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.